Journal of Clinical Endocrinology & Metabolism, Vol 80, 836-840, Copyright © 1995 by Endocrine Society

ARTICLES

Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads

D Travia, F Tosi, C Negri, G Faccini, P Moghetti and M Muggeo
Cattedra di Malattie del Metabolismo, University of Verona, Italy.

Plasma lipoproteins are a major source of cholesterol for steroid hormone synthesis. 3-Hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitors, which reduce both intracellular cholesterol synthesis and serum cholesterol levels, thus have a potential negative impact on steroidogenesis. In this study, we evaluated basal and maximally stimulated adrenocortical and testicular steroidogenesis in 24 hypercholesterolemic male subjects during 6-36 months of statin treatment. One group was evaluated before treatment and after 6 months of treatment. A second group, which received long term treatment, was evaluated after 24-36 months and then 2 months after treatment had been discontinued. Fourteen subjects were given simvastatin, and 12 were given pravastatin, both at the maximum therapeutic dosage of 40 mg/day. During statin therapy, serum cholesterol was lowered by about 30%. Basal serum and urinary cortisol levels as well as serum cortisol response to ACTH were not influenced by statin therapy. Basal serum testosterone and its response to hCG were also unchanged by statin treatment. In addition, steroid hormone urinary metabolites were strikingly similar when patients were given HMG-CoA reductase inhibitors and when they were not. These results indicate that maximum therapeutic doses of statins have no negative impact on adrenocortical and testicular steroidogenesis even when these glands are maximally stimulated.

This article has been cited by other articles:

				R.M. Reynolds, B. Ilyas, J.F. Price, F.G.R. Fowkes, D.E. Newby, D.J. Webb, and B.R. Walker Circulating plasma cortisol concentrations are not associated with coronary artery disease or peripheral vascular disease QJM, July 1, 2009; 102(7): 469 - 475. [Abstract] [Full Text] [PDF]

				R. D. Stanworth, D. Kapoor, K. S. Channer, and T. H. Jones Statin Therapy Is Associated With Lower Total but Not Bioavailable or Free Testosterone in Men With Type 2 Diabetes Diabetes Care, April 1, 2009; 32(4): 541 - 546. [Abstract] [Full Text] [PDF]

				I. Romao, E. Klass, P. J. Westenend, R. Storm, R. J. Oostenbroek, and G. D. Braunstein Gynecomastia N. Engl. J. Med., December 20, 2007; 357(25): 2636 - 2637. [Full Text] [PDF]

				S.-Y. Zhang, Y. Ito, O. Yamanoshita, Y. Yanagiba, M. Kobayashi, K. Taya, C. Li, A. Okamura, M. Miyata, J. Ueyama, et al. Permethrin May Disrupt Testosterone Biosynthesis via Mitochondrial Membrane Damage of Leydig Cells in Adult Male Mouse Endocrinology, August 1, 2007; 148(8): 3941 - 3949. [Abstract] [Full Text] [PDF]

				S. A Linnebur and W. H Hiatt Probable Statin-Induced Testicular Pain Ann. Pharmacother., January 1, 2007; 41(1): 138 - 142. [Abstract] [Full Text] [PDF]

				M. E. Zanolin, F. Tosi, G. Zoppini, R. Castello, G. Spiazzi, R. Dorizzi, M. Muggeo, and P. Moghetti Clustering of Cardiovascular Risk Factors Associated With the Insulin Resistance Syndrome: Assessment by principal component analysis in young hyperandrogenic women Diabetes Care, February 1, 2006; 29(2): 372 - 378. [Abstract] [Full Text] [PDF]

				L. A. Dostal, P. Juneau, and C. E. Rothwell Repeated Analysis of Semen Parameters in Beagle Dogs during a 2-Year Study with the HMG-CoA Reductase Inhibitor, Atorvastatin Toxicol. Sci., May 1, 2001; 61(1): 128 - 134. [Abstract] [Full Text] [PDF]

				K.M English, O Mandour, R.P Steeds, M.J Diver, T.H Jones, and K.S Channer Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms Eur. Heart J., June 1, 2000; 21(11): 890 - 894. [Abstract] [PDF]

				R. H. Knopp Drug Treatment of Lipid Disorders N. Engl. J. Med., August 12, 1999; 341(7): 498 - 511. [Full Text] [PDF]

				J. L. Isaacsohn, R. G. Bakker-Arkema, R. Fayyad, R. Whitcomb, and D. M. Black Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients with Hypercholesterolemia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 243 - 249. [Abstract] [PDF]